# A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin

> **NCT03332212** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 72 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03332212
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2020-05-21
- **Final completion:** 2020-05-28
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2021-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332212, "A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03332212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*